Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensity-adjusted Salvage Chemotherapy Plus Gilteritinib in Relapsed/Refractory FLT3-mutated AML
KCT0006222Phase 2Not yet recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0006222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006222.